Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac for the season 2008/2009. An open-label, baseline-controlled multi-center study in two groups: Adult subjects and elderly subjects.

Trial Profile

Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac for the season 2008/2009. An open-label, baseline-controlled multi-center study in two groups: Adult subjects and elderly subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 15 Mar 2012 Actual initiation date changde from Jun 2008 to 25 may 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned end date changed from 1 Jul 2008 to 25 May 2009 as reported by European Clinical Trials Database.
    • 12 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top